The Chinese biopharmaceutical industry has reportedly entered an innovation phase (2.0), focusing on commercialising its products, which might lead to surpassing the US in pharmaceutical market leader...

Recent analyses have shown that China's pharmaceutical output has matched the United States, with new drug discoveries tripling from about 30 in 2013 to over 400 by a decade later. This achievement ma...

Chinese pharmaceutical companies have recently engaged in multiple out-licensing agreements with international partners, highlighting China’s increasing significance as a source for innovative medicin...

HC Wainwright raised its target price for KalVista Pharmaceuticals (NASDAQ:KALV) stock from $27.00 to $37.00, maintaining a 'buy' rating. The analyst report was distributed to investors on Friday....

The EU's health-related policies and regulations have significantly benefited both the pharmaceutical and food industries. These sectors have seen advantages as a result of regulatory frameworks desig...

UnitedHealth Group, Eli Lilly and Company, Thermo Fisher Scientific, Tempus AI, and Johnson & Johnson are highlighted as key medical stocks to observe today by MarketBeat's stock screener tool. These ...

Analysts at BTIG Research initiated coverage of Bicara Therapeutics stock on NASDAQ, assigning a 'buy' rating and setting a price target of $28.00 per share, which represents a potential upside of 56%...